James Fotheringham

Understanding variation between kidney centres in implementation of tolvaptan in the management of autosomal dominant polycystic kidney disease: a multiple case study

Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) affects an estimated 12.5 million people worldwide and 70,000 in the United Kingdom (UK). Tolvaptan is the only disease-modifying therapy available. Despite national guidelines, prescribing varies across UK...